Key facts
- Reglagene’s last known valuation is $6.3M (Dec 2020).
- It has raised $13.6M; the latest was Later Stage VC in Jan 2026.
- Notable investors include Arizona Commerce Authority, Viva BioInnovator, Flinn Foundation, Angel Star Ventures, Brain Tumour Research Novel Therapeutics Accelerator — 15 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 15 names
- ·Watchlist + deal alerts for Reglagene
- ·The full record, as it builds
Funding rounds
No funding rounds for Reglagene are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Reglagene
Operator of a therapeutics company intended to transform tubulin targeting therapy for central nervous system diseases. The company's lead program is a novel, orally administered, well-tolerated, blood-brain barrier penetrant therapy for the treatment of brain cancers, product's portfolio includes disease indications driven by brain inflammation and ocular neovascularization, enabling medical practitioners to treat cancer and other diseases in which changes in gene processing rate are causal.
- Sector
- Healthcare
- HQ
- Houston, TX, United States
- Founded
- 2016
- Employees
- 12
- Website
- reglagene.com/
- Ownership
- Privately Held (backing)
Reglagene doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Reglagene shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Reglagene in its N-PORT filings yet. We sweep new filings monthly.